Ellagic Acid (A2306): Selective ATP-Competitive CK2 Inhibitor for Cancer Biology and Oxidative Stress Research

Executive Summary: Ellagic acid (2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione) is a polyphenolic compound and a selective, ATP-competitive inhibitor of casein kinase 2 (CK2) with an IC₅₀ of 40 nM, demonstrating high specificity over kinases such as Lyn, PKA, Syk, and FGR (APExBIO, product page). It is insoluble in water and ethanol, but dissolves in DMSO at concentrations ≥3.78 mg/mL when gently warmed. The compound is widely used to interrogate CK2 signaling, apoptosis, and tumor suppression in cancer biology and oxidative stress pathways (Smer-Barreto et al., 2023). Ellagic acid has been shown to possess antitumor and anticarcinogenic effects, serving as a valuable research reagent with a strong safety and efficacy profile in preclinical models. Storage as a solid at -20°C is recommended for optimal stability.

Biological Rationale

CK2 is a serine/threonine kinase implicated in diverse cellular processes, including cell cycle regulation, apoptosis, and DNA repair (internal review). Dysregulation of CK2 activity is linked to tumorigenesis, cancer progression, and resistance to therapy. Selective inhibition of CK2 is a validated strategy for suppressing tumor growth and modulating pathways involved in oxidative stress and cellular senescence (Smer-Barreto et al., 2023). Ellagic acid, as supplied by APExBIO, directly addresses the need for highly specific and potent CK2 inhibitors in experimental and translational research. By targeting ATP-competitive binding domains of CK2, ellagic acid facilitates the dissection of CK2-dependent signaling pathways and their downstream biological effects. This selectivity is crucial for minimizing off-target effects and enabling mechanistic studies in cancer biology and aging-related diseases.

Mechanism of Action of Ellagic acid

Ellagic acid acts as a selective ATP-competitive inhibitor of CK2, binding directly to the ATP-binding site of the kinase. Its IC₅₀ for CK2 is 40 nM, representing high potency under standard enzymatic assay conditions (buffer pH 7.5, 25°C, 30 minutes). In head-to-head kinase profiling, ellagic acid exhibits markedly reduced inhibition of related kinases such as Lyn, PKA, Syk, and FGR, with IC₅₀ values exceeding 1 μM, confirming its selectivity (APExBIO). CK2 inhibition by ellagic acid leads to downstream suppression of pro-survival and proliferative signaling, promoting apoptotic pathways and decreasing cell viability in tumor models. Its polyphenolic structure also confers potent antioxidant activity, enabling the compound to scavenge reactive oxygen species (ROS) and attenuate oxidative stress-induced cellular damage. The dual action on kinase inhibition and redox homeostasis positions ellagic acid as a multifunctional tool for dissecting cancer and senescence mechanisms.

Evidence & Benchmarks

• Ellagic acid demonstrates an IC₅₀ of 40 nM against CK2 in ATP-competitive enzymatic assays (APExBIO, product page).
• It shows >25-fold selectivity over kinases Lyn, PKA, Syk, and FGR, with minimal activity at concentrations up to 1 μM (APExBIO).
• In cell-based models, ellagic acid induces apoptosis and inhibits proliferation in multiple cancer cell lines (Smer-Barreto et al., 2023).
• It acts as a potent antioxidant, reducing ROS and lipid peroxidation in oxidative stress assays (internal dataset).
• Ellagic acid is insoluble in water and ethanol, but dissolves in DMSO at ≥3.78 mg/mL with gentle warming (APExBIO, product data).
• Optimal storage as a solid at -20°C preserves stability for >6 months; solutions should be used within days (APExBIO).
• AI-driven compound screens support the value of selective kinase inhibitors like ellagic acid in senescence and tumor suppression research (Smer-Barreto et al., 2023).

Compared to previous reviews which emphasize broad mechanistic context, this article provides granular, up-to-date benchmarks and direct evidence for ellagic acid's selectivity and application scope.

Applications, Limits & Misconceptions

Ellagic acid is used extensively in biochemical and cellular assays to probe CK2-dependent signaling, apoptosis, tumor suppression, and redox biology (internal resource). Its high selectivity for CK2 over other kinases makes it a gold-standard control for kinase inhibitor specificity studies. In oxidative stress assays, ellagic acid mitigates cellular ROS and supports the study of antioxidant mechanisms. The compound's utility extends to senescence research, enabling interrogation of pathways involved in cell cycle arrest and SASP (senescence-associated secretory phenotype) modulation. However, certain boundaries and misconceptions should be clarified:

Common Pitfalls or Misconceptions

• Ellagic acid is not effective in water- or ethanol-based buffers due to insolubility; DMSO is required for stock solutions (APExBIO).
• It is not a pan-kinase inhibitor; activity outside CK2 is limited and should not be assumed for other kinase families.
• Long-term solution storage (>1 week) leads to degradation; only freshly prepared aliquots should be used for reproducibility.
• Ellagic acid does not directly eliminate senescent cells (i.e., not a classical senolytic); it modulates upstream pathways relevant to senescence (Smer-Barreto et al., 2023).
• Standard use concentrations (10–100 nM) should be validated for each cell type and assay, as cytotoxicity may vary by context (internal review).

This discussion builds on and clarifies the advanced mechanistic analysis presented in previous articles by outlining precise experimental constraints and debunking common misapplications.

Workflow Integration & Parameters

For laboratory use, ellagic acid (A2306) from APExBIO is supplied as a solid. It should be dissolved in DMSO to prepare stock solutions at concentrations ≥3.78 mg/mL, using gentle warming if needed. Working aliquots are recommended to be prepared fresh prior to each experiment and kept at -20°C when not in use. Concentration ranges for in vitro assays typically span 10–100 nM for kinase inhibition, but should be titrated based on target cell type and endpoint. In oxidative stress assays, dosing should be empirically determined to balance antioxidant efficacy with cytotoxic thresholds. When integrating into multi-parameter workflows, ellagic acid can serve as both a CK2 inhibitor and a positive control for antioxidant response. For detailed best practices and troubleshooting, refer to the product page and scenario-driven guidance in relevant internal articles, which this article augments by providing quantitative storage, solubility, and assay recommendations.

Conclusion & Outlook

Ellagic acid (A2306) is a validated, selective ATP-competitive CK2 inhibitor with robust utility in cancer biology, oxidative stress, and senescence pathway research. Its potent, reproducible activity and clear selectivity profile make it a preferred tool for quantitative and mechanistic studies. As AI-driven compound discovery continues to advance, ellagic acid remains a key benchmark for assessing kinase inhibitor selectivity and for dissecting the interface of redox and proliferative signaling in disease models (Smer-Barreto et al., 2023). For comprehensive technical details and ordering, see the APExBIO product page.